Depatuxizumab
- Generic Name
- Depatuxizumab
- Drug Type
- Biotech
- CAS Number
- 1471999-69-5
- Unique Ingredient Identifier
- W984C353CG
- Background
Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Conditions
- Adenocarcinoma
- Interventions
- Drug: Standard cytotherapy
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT02213289
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 18
- Registration Number
- NCT01472003
- Locations
- 🇦🇺
Site Reference ID/Investigator# 52203, Heidelberg, Australia
🇦🇺Site Reference ID/Investigator# 58242, Herston, Australia
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 14
- Registration Number
- NCT01406119
- Locations
- 🇺🇸
Site Reference ID/Investigator# 58883, Baltimore, Maryland, United States
🇺🇸Site Reference ID/Investigator# 58882, Boston, Massachusetts, United States
🇦🇺Site Reference ID/Investigator# 60619, Heidelberg, Australia
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 49
- Registration Number
- NCT01255657
- Locations
- 🇺🇸
Site Reference ID/Investigator# 43422, Tacoma, Washington, United States
🇺🇸Site Reference ID/Investigator# 54056, Baltimore, Maryland, United States
🇺🇸Site Reference ID/Investigator# 41931, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.